BioTime (BTX) To Collaborate With The University of Wisconsin And Louvain University In Test Of Hystem®-Based Hydrogel For Vocal Fold Scarring
8/28/2014 10:23:31 AM
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX) today announced that it has entered into a collaboration with Susan Thibeault, Ph.D., of the University of Wisconsin and Marc Remacle, M.D. of Louvain University to evaluate BioTime’s proprietary HyStem®-based hydrogel for the treatment of vocal fold scarring. Preclinical studies published by Dr. Thibeault and her colleagues have demonstrated that localized delivery of HyStem® into injured vocal folds resulted in a significant improvement in function. Under a sponsored research agreement, Dr. Thibeault’s laboratory will evaluate HyStem®-based hydrogels to identify formulations with optimum properties for reducing scarring. Upon completion of these preclinical studies, an investigator-initiated clinical trial in patients with vocal fold scarring due to disease or prior surgical interventions is planned, under the direction of Dr. Remacle, at the Cliniques Universitaires UCL Mont-Godinne in Belgium, subject to institutional and regulatory approval.
Help employers find you! Check out all the jobs and post your resume.
comments powered by